People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Revolutionary nasal spray offers hope by potentially delaying Alzheimer's progression through cutting-edge neurological ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
Researchers delivered a dose of the “love hormone” oxytocin via a nasal spray to participants and found that it decreased ...
The FDA has approved the use of Spravato, an antidepressant nasal spray, as a standalone treatment for depression in the U.S. Sue Varma discusses why she supports the use of the drug and how it may ...
"We are pleased the FDA has accepted our NDA for Bumetanide Nasal Spray," said Benjamin Esque, CEO of Corstasis Therapeutics ...
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...
The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.
Dr. Syed Hussain from Trinity Health of New England discusses the latest health news from around the country and the world.
Spravato, a newly FDA-approved nasal spray, offers hope for individuals with treatment-resistant depression, a condition ...